An ascending dose study to determine the safety and effect of antibodies against hepatitis B (The SAMBA Study)

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508444-22-01

Acronym

SAMBA-001

Enrollment

Registered

2024-06-28

Start date

2024-08-26

Completion date

Unknown

Last updated

2025-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis B infection

None listed

Sex/Gender

All

Age

18 Years to No maximum

Denmark, Germany

None listed

Source: EU CTIS · Data processed: Feb 4, 2026